Claims
- 1. A 5-substituted indan-2-carboxylic acid or functional derivative thereof having the formula ##STR32## in which R is selected from the group consisting of cyclohexyl, phenyl, phenyl-alkenyl, phenyl-alkyl, and phenyl substituted by a substituent selected from the group consisting of halogen atoms, alkyl, alkoxy, acetamido, amino, dialkylamino, nitro, phenyl, alkylsulfonyl, dialkylaminosulfonyl and sulfamido groups, in the free form or a therapeutically acceptable salt or amide thereof, or a therapeutically acceptable ester selected from the group consisting of alkyl, dialkylaminoalkyl and cinnamoylamidoalkyl carboxylic acid esters.
- 2. The compound of claim 1 wherein said therapeutically acceptable amide is selected from the group consisting of the dihydro, 2-hydroxyethyl and dialkylaminoalkyl carboxamides.
- 3. The compound of claim 1 comprising the acid in which R is phenyl.
- 4. The compound of claim 1 comprising the methyl ester in which R is phenyl.
- 5. The compound of claim 1 comprising the dialkylaminoalkyl ester in which R is phenyl.
- 6. The compound of claim 1 wherein R is a phenyl radical substituted by at least one substituent selected from the group consisting of the halogen atoms and the acetamido, dialkylamino, alkylsulfonyl, dialkylaminosulfonyl and sulfamido groups.
- 7. The compound of claim 6 wherein R is a phenyl radical substituted by at least one substituent selected from the group consisting of chlorine, and the acetamido, dimethylamino, methylsulfonyl, dimethylsulfonyl and sulfamido groups.
- 8. The compound of claim 1 in the form of a therapeutically acceptable amide wherein said amide comprises the dialkylaminoalkyl carboxamide.
- 9. The therapeutic composition for combatting inflammation and pain comprising an anti-inflammatory or analgesic amount of a compound in accordance with claim 1 and a pharmaceutically acceptable excipient therefor.
- 10. The composition in accordance with claim 9 wherein said compound is the acid in which R is phenyl.
- 11. The composition in accordance with claim 9 in unit dosage form, each unit dose comprising from 50 to 500 mg of said compound.
- 12. The composition in accordance with claim 10 in unit dosage form, each unit dose comprising from 50 to 500 mg of said compound.
Priority Claims (3)
Number |
Date |
Country |
Kind |
76 00552 |
Jan 1976 |
FRX |
|
76 37754 |
Dec 1976 |
FRX |
|
77 33496 |
Nov 1977 |
FRX |
|
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is a continuation-in-part of U.S. application Ser. No. 756,862, filed Jan. 4, 1977, now abandoned, the entire contents of which are hereby incorporated by reference.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3953500 |
Noguchi et al. |
Apr 1976 |
|
4057573 |
Haas et al. |
Nov 1977 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
849285 |
Jun 1977 |
BEX |
Non-Patent Literature Citations (2)
Entry |
Kirsch et al., Ann. 1976, pp. 1914-1924. |
Noguchi et al., Japan Kokai 74-80053, as cited in Chem. Abstracts 82, 15594f (1975). |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
756862 |
Jan 1977 |
|